key: cord-0922601-dlrzi9e4
authors: van Dijk, Merel M.H.; Veldman, Hidde D.; Aarts, Frits; Barten, Dennis G.; van den Bergh, Joop P
title: A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis.
date: 2021-11-27
journal: Ann Hepatol
DOI: 10.1016/j.aohep.2021.100590
sha: 2069a0fb90a5a78ce08627850ca9f0f45d61c2bf
doc_id: 922601
cord_uid: dlrzi9e4

nan

To the editor, Much effort has been executed in developing and testing the effectiveness and safety of vaccines for SARS-CoV-2 (Coronavirus COVID-19) in the currently ongoing pandemic.

One of the vaccines that has been approved on the global market is the AstraZeneca ChAdOx1 nCov-19 vaccine [1, 2] . Strict documentation of complications and side effects enabled us to gain insight into the potential risks of the vaccine [1, 2] . Since its introduction cases have been reported with complications such as thrombosis, thrombocytopenia and coagulation disorders such as a deviating D-dimer count and abnormalities in the international normalized ratio, partial thromboplastin time or fibrinogen level. Potentially, this resulted in cerebral venous sinus thrombosis (CVST), splanchnic vein thrombosis (SVT), as well as arterial thrombosis [3] [4] [5] [6] .

With great interest we have read the editorial article entitled 'COVID-19 vaccineinduced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis.' that was published in the April's issue of the journal [7] . In this article, the authors propose a stepwise protocol for clinicians aiming to detect the clinical cases of vaccine-induced immune thrombotic thrombocytopenia (VITT) so that adequate therapy can be administered in a timely matter. Regarding SVT in particular, the authors advise to further investigate patients with abdominal symptoms after receiving the AstraZeneca ChAdOx1 nCov-19 vaccine. The associated symptoms that were listed contained: severe abdominal pain, nausea/vomiting, melena or haematochezia and/or persistent high fevers. Although this may be adequate for most cases, we hereby report a case of VITT with SVT that was presented to our emergency department (ED) with a rather mild symptomatology. Treatment with rivaroxaban 15mg twice a day was initiated immediately as SVT was observed on the CTA. Additionally, after the positive ELISA test for VITT, treatment with intravenous immunoglobulin (IVIG) was initiated. Discharge followed after administration of IVIG for two days. Monitoring of the patients' blood showed a rise in thrombocytes to 129 10 9 /l after 2 days of IVIG administration. Treatment with rivaroxaban was continued for a total of three months. During follow-up two weeks after discharge, the patient reported the symptoms to be significantly less. No additional blood test were performed at that time. The patient continues to be monitored.

In summary, the editorial article [7] and its recommendations are not all-encompassing in detecting VITT. In response, we present a case of VITT with SVT following the administration of AstraZeneca vaccine. The patient in this case presented with mild symptomology unlike the patients described in the editorial article [7] . We conclude that even in patients presenting with mild abdominal symptoms after receiving the AstraZeneca vaccine there is a possibility of VITT. Our case had none of the symptoms that were listed in the stepwise protocol of the editorial article [7] as potentially pointing towards VITT with SVT.

This patient would have been overlooked if the protocol was followed with the risk of progression of thrombosis and more life-threatening symptoms. Thankfully, early detection was achieved. In conclusion, mild abdominal symptoms do not exclude the presence of VITT.

Therefore, we propose that in patients with mild abdominal symptoms after a recent vaccination with AstraZeneca ChAdOx1 nCov-19 vaccine should also be considered in the step-wise protocol to detect VITT. Furthermore, additional blood tests for platelet count and D-dimer can lead to the correct diagnosis.

Coronavirus Pandemic (COVID-19). Retrieved from

World Health Organisation (2020) WHO Coronavirus (COVID-19) Dashboard. Retrieved from

AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

AstraZeneca's COVID-19 vaccine: benefits and risks in context

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis